

Special Issue

Personalized Medicine in Minimally Invasive Urological Surgery

Message from the Guest Editors

Modern medicine faces numerous challenges, including the tendency to swing between overtreatment and undertreatment. The challenge is striking the right balance between adequate treatment and avoiding harm. Thanks to innovations in technology and progress in our understanding of biology, personalized medicine offers a solution to this challenge by delivering the right therapy at the right time to the right patient.

Personalized medicine takes into account individual differences in people's characteristics to create a unique and effective treatment plan. This approach allows for more precise and targeted therapy, reducing the risk of overtreatment or undertreatment and improving patient outcomes. This Special Issue of the *Journal of Personalized Medicine* is open to all minimally invasive surgical procedures for the treatment of either benign or malignant genitourinary diseases.

Guest Editors

Prof. Dr. Costantino Leonardo

Department of Maternal-Infant and Urological Sciences, "Sapienza" Rome University, Policlinico Umberto I Hospital, 00185 Rome, Italy

Dr. Antonio Tufano

Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza University Rome, 00162 Rome, Italy

Deadline for manuscript submissions

closed (10 February 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/165470

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).